logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 20 of 77 Items
Showing 1 - 20 of 77 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Review

Systematic review on cumulative HIV viraemia among people living with HIV receiving antiretroviral treatment and its association with mortality and morbidity

Mesic A, Decroo T, Florence E, Ritmeijer KKD, van Olmen J,  et al.
2024-05-01 • International Health
2024-05-01 • International Health
BACKGROUND
We performed a systematic review to generate evidence on the association between cumulative human immunodeficiency virus (HIV) viraemia and health outcomes.

METHO...
Journal Article
|
Research

Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial

Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N,  et al.
2024-02-01 • Lancet Respiratory Medicine
2024-02-01 • Lancet Respiratory Medicine
BACKGROUND
Around 500,000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are nee...
Journal Article
|
Case Report/Series

Chronic high level parasitemia in HIV-infected individuals with or without visceral leishmaniasis in an endemic area in North-West Ethiopia: potential superspreaders?

van Griensven J, van Henten S, Kibret A, Kassa M, Beyene H,  et al.
2024-01-09 • Clinical Infectious Diseases
2024-01-09 • Clinical Infectious Diseases
BACKGROUND
HIV patients with recurrent visceral leishmaniasis (VL) could potentially drive Leishmania transmission in areas with anthroponotic transmission such as East-Africa, but s...
Journal Article
|
Protocol

Haematological dynamics following treatment of visceral leishmaniasis: a protocol for systematic review and individual participant data (IPD) meta-analysis

Munir A, Dahal P, Kumar R, Singh-Phulgenda S, Siddiqui NA,  et al.
2023-12-14 • BMJ Open
2023-12-14 • BMJ Open
INTRODUCTION
Visceral leishmaniasis (VL) is a parasitic disease with an estimated 30,000 new cases occurring annually. Despite anaemia being a common haematological manifestation of ...
Journal Article
|
Protocol

Host, parasite and drug determinants of clinical outcomes following treatment of visceral leishmaniasis: a protocol for individual participant data meta-analysis

Kumar R, Dahal P, Singh-Phulgenda S, Siddiqui NA, Munir A,  et al.
2023-10-28 • BMJ Open
2023-10-28 • BMJ Open
INTRODUCTION
Visceral leishmaniasis (VL) is a parasitic disease with an estimated 30 000 new cases occurring annually. There is an observed variation in the efficacy of the current f...
Journal Article
|
Research

Proportion of paediatric admissions with any stage of noma at the Anka General Hospital, northwest Nigeria

Farley ES, Karinja MN, Lawal AM, Olaleye M, Muhammad S,  et al.
2023-10-27 • PLOS Neglected Tropical Diseases
2023-10-27 • PLOS Neglected Tropical Diseases
INTRODUCTION
Noma is a rapidly spreading infection of the oral cavity which mainly affects young children. Without early treatment, it can have a high mortality rate. Simple gingivit...
Journal Article
|
Editorial

Therapeutic strategies against leishmania and trypanosoma

Santos ALS, Rodrigues IA, d’Avila-Levy CM, Sodré CL, Ritmeijer KKD,  et al.
2023-10-19 • Pathogens
2023-10-19 • Pathogens
Human African trypanosomiasis (also known as sleeping sickness, with Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense as etiological agents), American trypanosomiasis (als...
Journal Article
|
Research

Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis

Verrest L, Roseboom IC, Wasunna M, Mbui J, Njenga SN,  et al.
2023-09-20 • Journal of Antimicrobial Chemotherapy
2023-09-20 • Journal of Antimicrobial Chemotherapy
OBJECTIVES
To improve visceral leishmaniasis (VL) treatment in Eastern Africa, 14- and 28-day combination regimens of paromomycin plus allometrically dosed miltefosine were evaluated...
Conference Material
|
Slide Presentation

Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial

Solomos A, Musa AM, Mbui J, Mohammed R, Olobo J,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
Conference Material
|
Abstract

Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial

Solomos A, Musa AM, Mbui J, Mohammed R, Olobo J,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
INTRODUCTION
The parasitic disease visceral leishmaniasis (VL) is most commonly caused by Leishmania donovani in eastern Africa, currently the region with highest burden worldwide. C...
Journal Article
|
Commentary

Anticipating visceral leishmaniasis epidemics due to the conflict in Northern Ethiopia

Boodman C, van Griensven J, Gupta N, Diro EGJ, Ritmeijer KKD
2023-03-23 • PLOS Neglected Tropical Diseases
2023-03-23 • PLOS Neglected Tropical Diseases
Journal Article
|
Commentary

Snakebite envenoming at MSF: A decade of clinical challenges and antivenom access issues

Potet J, Singh SN, Ritmeijer KKD, Sisay K, Alcoba G,  et al.
2022-12-21 • Toxicon: X
2022-12-21 • Toxicon: X
The medical humanitarian organization Médecins Sans Frontières (MSF) provides medical care in more than 70 countries and admits more than 7000 cases of snakebite in its facilities each y...
Journal Article
|
Research

Advanced HIV disease and associated attrition after re-engagement in HIV care in Myanmar from 2003 to 2019: a retrospective cohort study

Mesic A, Homan T, Lenglet AD, Thit P, Mar HT,  et al.
2022-11-01 • International Health
2022-11-01 • International Health
BACKGROUND
The burden of advanced HIV disease (AHD) and predictors of outcomes among people living with HIV (PLHIV) re-engaging in care are not well known.

METHODS
We co...
Journal Article
|
Research

Paromomycin and miltefosine combination as an alternative to treat patients with visceral leishmaniasis in Eastern Africa: A randomized, controlled, multicountry trial

Musa AM, Mbui J, Mohammed R, Olobo J, Ritmeijer KKD,  et al.
2022-09-27 • Clinical Infectious Diseases
2022-09-27 • Clinical Infectious Diseases
BACKGROUND
This study aimed to determine whether paromomycin plus miltefosine (PM/MF) is noninferior to sodium stibogluconate plus paromomycin (SSG/PM) for treatment of primary visce...
Journal Article
|
Research

The increasing incidence of visceral leishmaniasis relapse in South Sudan: A retrospective analysis of field patient data from 2001–2018

Naylor-Leyland G, Collin SM, Gatluak F, den Boer ML, Alves F,  et al.
2022-08-18 • PLOS Neglected Tropical Diseases
2022-08-18 • PLOS Neglected Tropical Diseases
BACKGROUND
Visceral Leishmaniasis (VL) is endemic in South Sudan, manifesting periodically in major outbreaks. Provision of treatment during endemic periods and as an emergency respo...
Journal Article
|
Research

Viraemic-time predicts mortality among people living with HIV on second-line antiretroviral treatment in Myanmar: A retrospective cohort study

Mesic A, Decroo T, Mar HT, Jacobs BKM, Thandar MP,  et al.
2022-07-29 • PLOS One
2022-07-29 • PLOS One
INTRODUCTION
Despite HIV viral load (VL) monitoring being serial, most studies use a cross-sectional design to evaluate the virological status of a cohort. The objective of our study...
Journal Article
|
Research

Field evaluation of rK39 test and direct agglutination test for diagnosis of visceral leishmaniasis in a population with high prevalence of human immunodeficiency virus in Ethiopia

ter Horst R, Tefera T, Assefa G, Ebrahim AZ, Davidson RN,  et al.
2009-06-01 • American Journal of Tropical Medicine and Hygiene
2009-06-01 • American Journal of Tropical Medicine and Hygiene
Accuracy of an rK39 rapid diagnostic test (DiaMed-IT-Leish ) for visceral leishmaniasis (VL) was compared with splenic aspiration and the direct agglutination test (DAT) in a population ...
Journal Article
|
Research

Development and external validation of a clinical prognostic score for death in visceral leishmaniasis patients in a high HIV co-infection burden area in Ethiopia

Abongomera C, Ritmeijer KKD, Vogt F, Buyze J, Mekonnen Z,  et al.
2017-06-05 • PLOS One
2017-06-05 • PLOS One
BACKGROUND
In Ethiopia, case fatality rates among subgroups of visceral leishmaniasis (VL) patients are high. A clinical prognostic score for death in VL patients could contribute to...
Journal Article
|
Research

"Kala-Azar is a Dishonest Disease": Community Perspectives on Access Barriers to Visceral Leishmaniasis (Kala-Azar) Diagnosis and Care in Southern Gadarif, Sudan

Sunyoto T, Adam GK, Atia AM, Hamid Y, Babiker RA,  et al.
2018-02-22 • American Journal of Tropical Medicine and Hygiene
2018-02-22 • American Journal of Tropical Medicine and Hygiene
Early diagnosis and treatment is the principal strategy to control visceral leishmaniasis (VL), or kala-azar in East Africa. As VL strikes remote rural, sparsely populated areas, kala-az...
Journal Article
|
Research

Failure of an Innovative Low-Cost, Noninvasive Thermotherapy Device for Treating Cutaneous Leishmaniasis Caused by in Pakistan

Kamink SS, Abdi AM, Kamau C, Ashraf S, Ansari MA,  et al.
2019-10-07 • American Journal of Tropical Medicine and Hygiene
2019-10-07 • American Journal of Tropical Medicine and Hygiene
Cutaneous leishmaniasis (CL), a neglected parasitic skin disease, is endemic in Pakistan, where Leishmania tropica and Leishmania major are the causative protozoan species. Standard trea...